Getting arthritis gene therapy into the clinic

Christopher H Evans, Steven C. Ghivizzani, Paul D. Robbins

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Gene transfer technologies enable the controlled, targeted and sustained expression of gene products at precise anatomical locations, such as the joint. In this way, they offer the potential for more-effective, less-expensive treatments of joint diseases with fewer extra-articular adverse effects. A large body of preclinical data confirms the utility of intra-articular gene therapy in animal models of rheumatoid arthritis and osteoarthritis. However, relatively few clinical trials have been conducted, only one of which has completed phase II. This article summarizes the status in 2010 of the clinical development of gene therapy for arthritis, identifies certain constraints to progress and suggests possible solutions.

Original languageEnglish (US)
Pages (from-to)244-249
Number of pages6
JournalNature Reviews Rheumatology
Volume7
Issue number4
DOIs
StatePublished - Apr 2011
Externally publishedYes

Fingerprint

Genetic Therapy
Arthritis
Joints
Technology Transfer
Joint Diseases
Osteoarthritis
Rheumatoid Arthritis
Animal Models
Clinical Trials
Gene Expression
Genes
Therapeutics

ASJC Scopus subject areas

  • Rheumatology

Cite this

Getting arthritis gene therapy into the clinic. / Evans, Christopher H; Ghivizzani, Steven C.; Robbins, Paul D.

In: Nature Reviews Rheumatology, Vol. 7, No. 4, 04.2011, p. 244-249.

Research output: Contribution to journalArticle

Evans, Christopher H ; Ghivizzani, Steven C. ; Robbins, Paul D. / Getting arthritis gene therapy into the clinic. In: Nature Reviews Rheumatology. 2011 ; Vol. 7, No. 4. pp. 244-249.
@article{17fbb15ba17942d39d09b0b702a70daa,
title = "Getting arthritis gene therapy into the clinic",
abstract = "Gene transfer technologies enable the controlled, targeted and sustained expression of gene products at precise anatomical locations, such as the joint. In this way, they offer the potential for more-effective, less-expensive treatments of joint diseases with fewer extra-articular adverse effects. A large body of preclinical data confirms the utility of intra-articular gene therapy in animal models of rheumatoid arthritis and osteoarthritis. However, relatively few clinical trials have been conducted, only one of which has completed phase II. This article summarizes the status in 2010 of the clinical development of gene therapy for arthritis, identifies certain constraints to progress and suggests possible solutions.",
author = "Evans, {Christopher H} and Ghivizzani, {Steven C.} and Robbins, {Paul D.}",
year = "2011",
month = "4",
doi = "10.1038/nrrheum.2010.193",
language = "English (US)",
volume = "7",
pages = "244--249",
journal = "Nature Reviews Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Getting arthritis gene therapy into the clinic

AU - Evans, Christopher H

AU - Ghivizzani, Steven C.

AU - Robbins, Paul D.

PY - 2011/4

Y1 - 2011/4

N2 - Gene transfer technologies enable the controlled, targeted and sustained expression of gene products at precise anatomical locations, such as the joint. In this way, they offer the potential for more-effective, less-expensive treatments of joint diseases with fewer extra-articular adverse effects. A large body of preclinical data confirms the utility of intra-articular gene therapy in animal models of rheumatoid arthritis and osteoarthritis. However, relatively few clinical trials have been conducted, only one of which has completed phase II. This article summarizes the status in 2010 of the clinical development of gene therapy for arthritis, identifies certain constraints to progress and suggests possible solutions.

AB - Gene transfer technologies enable the controlled, targeted and sustained expression of gene products at precise anatomical locations, such as the joint. In this way, they offer the potential for more-effective, less-expensive treatments of joint diseases with fewer extra-articular adverse effects. A large body of preclinical data confirms the utility of intra-articular gene therapy in animal models of rheumatoid arthritis and osteoarthritis. However, relatively few clinical trials have been conducted, only one of which has completed phase II. This article summarizes the status in 2010 of the clinical development of gene therapy for arthritis, identifies certain constraints to progress and suggests possible solutions.

UR - http://www.scopus.com/inward/record.url?scp=79953662850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953662850&partnerID=8YFLogxK

U2 - 10.1038/nrrheum.2010.193

DO - 10.1038/nrrheum.2010.193

M3 - Article

VL - 7

SP - 244

EP - 249

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

SN - 1759-4790

IS - 4

ER -